{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:33:53Z","timestamp":1761766433151},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00292-018-0519-6","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T07:25:16Z","timestamp":1539242716000},"page":"556-562","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Leberschaden durch Therapie mit Immun-Checkpoint-Inhibitoren"],"prefix":"10.1007","volume":"39","author":[{"given":"B. K.","family":"Straub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Ridder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"issue":"10","key":"519_CR1","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1007\/s10620-006-9472-y","volume":"52","author":"W Bleibel","year":"2007","unstructured":"Bleibel W, Kim S, D\u2019Silva K, Lemmer ER (2007) Drug-induced liver injury: review article. Dig Dis Sci 52(10):2463\u20132471","journal-title":"Dig Dis Sci"},{"key":"519_CR2","first-page":"673","volume-title":"MacSweens Pathology of the Liver","author":"AD Burt","year":"2018","unstructured":"Burt AD, Ferrell LD, H\u00fcbscher SG (2018) MacSweens Pathology of the Liver, 7.\u00a0Aufl. Elsevier, Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney, Toronto, S\u00a0673\u2013779","edition":"7"},{"issue":"6","key":"519_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E Martin De","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J\u00a0Hepatol 68(6):1181\u20131190","journal-title":"J Hepatol"},{"issue":"1","key":"519_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000282065","volume":"28","author":"HP Dienes","year":"2010","unstructured":"Dienes HP, Drebber U (2010) Pathology of immune-mediated liver injury. Dig Dis 28(1):57\u201362","journal-title":"Dig Dis"},{"issue":"4","key":"519_CR5","doi-asserted-by":"publisher","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV, Parkinson CA, Corrie PG (2017) Severe steroid-resistant anti-PD1 T\u2011cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. Esmo Open 2(4):e268","journal-title":"Esmo Open"},{"key":"519_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, G\u00f6ppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190\u2013209","journal-title":"Eur J Cancer"},{"issue":"3","key":"519_CR7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a\u00a0novel form of serious liver injury. Ann Oncol 28(3):671\u2013672","journal-title":"Ann Oncol"},{"issue":"12","key":"519_CR8","doi-asserted-by":"publisher","first-page":"e51723","DOI":"10.1371\/journal.pone.0051723","volume":"7","author":"Y Guo","year":"2012","unstructured":"Guo Y, Fan Y, Qiu J, Liu Y, Gao J, Guo F (2012) Polymorphisms in CTLA4 influence incidence of drug-induced liver injury after renal transplantation in Chinese recipients. PLoS ONE 7(12):e51723","journal-title":"PLoS ONE"},{"issue":"8","key":"519_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","volume":"71","author":"DM Karamchandani","year":"2018","unstructured":"Karamchandani DM, Chetty R (2018) Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective. J\u00a0Clin Pathol 71(8):665\u2013671. https:\/\/doi.org\/10.1136\/jclinpath-2018-205143 . Epub 2018 Apr 27","journal-title":"J Clin Pathol"},{"issue":"6","key":"519_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ (2005) Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a\u00a0histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313\u20131321","journal-title":"Hepatology"},{"issue":"2","key":"519_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.gtc.2017.01.004","volume":"46","author":"DE Kleiner","year":"2017","unstructured":"Kleiner DE (2017) Drug-induced liver injury: the hepatic pathologist\u2019s approach. Gastroenterol Clin North Am 46(2):273\u2013296","journal-title":"Gastroenterol Clin North Am"},{"issue":"3","key":"519_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00292-017-0281-1","volume":"38","author":"VH Koelzer","year":"2017","unstructured":"Koelzer VH, Glatz K, Bubendorf L, Weber A, Gaspert A, Cathomas G, Lugli A, Zippelius A, Kempf W, Mertz KD (2017) The pathology of adverse events with immune checkpoint inhibitors. Pathologe 38(3):197\u2013208","journal-title":"Pathologe"},{"issue":"8","key":"519_CR13","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","volume":"23","author":"TG Neilan","year":"2018","unstructured":"Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA, Lindenfeld J, Murphy MJ, Moslehi JJ (2018) Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a\u00a0Call to Action. Oncologist 23(8):874\u2013878. https:\/\/doi.org\/10.1634\/theoncologist.2018-0157 . Epub 2018 May 25","journal-title":"Oncologist"},{"issue":"2","key":"519_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N\u00a0Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"6","key":"519_CR15","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/hep.23937","volume":"52","author":"A Reuben","year":"2010","unstructured":"Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group (2010) Drug-induced acute liver failure: results of a\u00a0U.S. multicenter, prospective study. Hepatology 52(6):2065\u20132076","journal-title":"Hepatology"},{"issue":"1","key":"519_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1055\/s-0033-1356224","volume":"52","author":"S R\u00f6sner","year":"2014","unstructured":"R\u00f6sner S, Schad A, Kittner J, Rahman F, W\u00f6rns MA, Schuchmann M, Galle PR, Schattenberg JM (2014) Drug-induced liver injury with an autoimmune phenotype following anti-TNF Therapy\u2014presentation of cases and review of literature. Z\u00a0Gastroenterol 52(1):58\u201363","journal-title":"Z Gastroenterol"},{"issue":"10","key":"519_CR17","first-page":"e1774","volume":"9","author":"D Simmons","year":"2017","unstructured":"Simmons D, Lang E (2017) The most recent oncologic emergency: what emergency physicians need to know about the potential complications of immune checkpoint inhibitors. Cureus 9(10):e1774","journal-title":"Cureus"},{"issue":"1","key":"519_CR18","doi-asserted-by":"publisher","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, G\u00f6ppner D, Dummer R, Heinzerling LM (2013) The price of tumor control: an analysis of rare side effects ofnanti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 8(1):e53745","journal-title":"PLoS ONE"},{"issue":"5","key":"519_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/ijc.30678","volume":"141","author":"W Wang","year":"2017","unstructured":"Wang W, Lie P, Guo M, He J (2017) Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer 141(5):1018\u20131028","journal-title":"Int J Cancer"},{"issue":"5","key":"519_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","volume":"37","author":"J Weber","year":"2010","unstructured":"Weber J (2010) Immune checkpoint proteins: a\u00a0new therapeutic paradigm for cancer\u2014preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 37(5):430\u2013439","journal-title":"Semin Oncol"},{"key":"519_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217744872","author":"KJ Williams","year":"2017","unstructured":"Williams KJ, Grauer DW, Henry DW, Rockey ML (2017) Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. J\u00a0Oncol Pharm Pract. https:\/\/doi.org\/10.1177\/1078155217744872 (Epub ahead of print)","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"519_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi R, Merghoub T, Wolchok JD (2018) Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 33(4):581\u2013598","journal-title":"Cancer Cell"},{"issue":"5","key":"519_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000486679","volume":"94","author":"K Zarrabi","year":"2018","unstructured":"Zarrabi K, Wu S (2018) Risk of liver toxicity with Nivolumab immunotherapy in cancer patients. Oncology 94(5):259\u2013273","journal-title":"Oncology"},{"key":"519_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0013-y","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM (2018) Hepatotoxicity of immune checkpoint inhibitors: a\u00a0histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. https:\/\/doi.org\/10.1038\/s41379-018-0013-y (Epub ahead of print)","journal-title":"Mod Pathol"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-018-0519-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-018-0519-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-018-0519-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T20:07:36Z","timestamp":1605211656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-018-0519-6"}},"subtitle":["Beispiel einer immunvermittelten Medikamentennebenwirkung"],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s00292-018-0519-6","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"11 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Loquai gibt folgende Interessenskonflikte an: Advisory-Board-Mitglied f\u00fcr BMS, MSD, Amgen, Roche, Novartis, Pierre Fabre, Leo, Idera und Sun Pharma; Vortragst\u00e4tigkeit f\u00fcr BMS, MSD, Amgen, Roche, Novartis, Pierre Fabre; Reiseunterst\u00fctzung von BMS, MSD, Amgen, Roche, Novartis, Pierre Fabre und Leo. B.\u00a0K.\u00a0Straub, D.\u00a0A.\u00a0Ridder, A.\u00a0Schad, und J.\u00a0M.\u00a0Schattenberg geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethik-Kommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Die Untersuchungen erfolgten unter Einhaltung der Vorgaben der Zentralen Ethikkommission der Bundes\u00e4rztekammer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}